글로벌 브루가다 증후군 치료 시장 - 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 글로벌 브루가다 증후군 치료 시장

글로벌 브루가다 증후군 치료 시장은 2021년부터 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 위에 언급된 예측 기간 동안 시장이 5.60%의 CAGR로 성장할 것으로 분석합니다.

브루가다 증후군은 위험한 불규칙한 심장 박동을 유발하는 희귀한 유전성 심혈관 질환입니다. 심장의 전기 시스템에 영향을 미치는 장애가 특징입니다. 심장 세포로의 나트륨 또는 칼륨 이온의 파괴로 인해 발생합니다. 이는 전기적 자극을 더욱 방해하여 매우 빠르고 생명을 위협하는 심장 리듬을 초래합니다. 이 질병의 일반적인 증상에는 발작 , 현기증, 실신, 헐떡거림 및 불규칙한 심장 박동이 포함됩니다.

브루가다 증후군 유병률 증가, 의료비 지출 증가, 치료 수요 증가, 진단 기술의 발전, 인식 확산을 위한 정부 이니셔티브 확대는 글로벌 브루가다 증후군 치료 시장을 확대할 요인입니다.

증가하는 R&D 활동, 첨단 치료법에 대한 수요 증가, 주요 제약 회사의 새로운 치료법에 대한 집중 등으로 인해 2021~2028년 예측 기간 동안 글로벌 브루가다 증후군 치료 시장에 유익한 기회가 제공될 것입니다.

심혈관 건강 관리 전문가 부족, 높은 치료 비용, 희귀 질환에 대한 인식 부족은 시장 성장을 방해하는 요인이며, 위에서 언급한 예측 기간 동안 글로벌 브루가다 증후군 치료 시장에 더욱 어려움을 겪을 것입니다.

This brugada syndrome treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global brugada syndrome treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Brugada Syndrome Treatment Market Scope and Market Size

The brugada syndrome treatment market is segmented on the basis of treatment, dosage, route of administration, diagnosis, end-users, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of treatment, the brugada syndrome treatment market is segmented into implantable cardioverter-defibrillator (ICD) and drug therapy. Drug therapy has been further sub-segmented into antiarrhythmic drugs, psychotropic drugs, anesthetics/analgesics, and others. Antiarrhythmic drugs have been further divided into ajmaline, allapinin, ethacizine, flecainide, pilsicainide, procainamide, propafenone, and other. Psychotropic drugs have been further divided into amitriptyline, clomipramine, desipramine, lithium, loxapine, nortriptyline, trifluoperazine, and others. Anesthetics/analgesics have been further divided into bupivacaine, procaine, propofol, and others.
• On the basis of dosage, the brugada syndrome treatment market is segmented into tablet, solution and others.
• On the basis of route of administration, the brugada syndrome treatment market is segmented into oral, intravenous, and others.
• On the basis of diagnosis, the brugada syndrome treatment market is segmented into electrocardiogram, electrophysiology (EP) test, genetic testing and others.
• On the basis of end-users, the brugada syndrome treatment market is segmented into clinic, hospital, and others.
• The brugada syndrome treatment market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy, and online pharmacy.

Global Brugada Syndrome Treatment Market Country Level Analysis

Global brugada syndrome treatment market is analyzed and market size information is provided by the country, treatment, dosage, route of administration, diagnosis, end-users, and distribution channel as referenced above.

The countries covered in the global brugada syndrome treatment market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the brugada syndrome treatment market due to the presence of major key players, well-developed healthcare sector, increasing prevalence of disease, and increasing awareness towards health in this region. Global brugada syndrome treatment market in the Asia-Pacific and Europe is expected to grow during the forecast period due to the increasing research and development activities, rise in number of insurance players, rising investment in the healthcare sector, and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Global brugada syndrome treatment market also provides you with detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Brugada Syndrome Treatment Market Share Analysis

Global brugada syndrome treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global brugada syndrome treatment market.

글로벌 브루가다 증후군 치료 시장 보고서에 포함된 주요 기업으로는 Boston Scientific Corporation, LivaNova PLC, Medtronic, Abbott, Edwards Lifesciences Corporation, Sun Pharmaceutical Industries Ltd., Novartis AG, ClearPoint Neuro, Inc., HeartSine Technologies LLC, GeneDx, Inc, GENERAL ELECTRIC COMPANY, Pfizer Inc., Lilly, GlaxoSmithKline plc, Taj Pharmaceuticals Limited 등이 있으며, 국내 및 글로벌 기업도 있습니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA), 남미에 대해 각각 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 개별적으로 제공합니다.

SKU-64274